Background: Tirzepatide (TZP), a unimolecular dual agonist targeting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, is a promising weight loss agent in obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.